Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Livzon Pharmaceutical Group","pharmaFlowCategory":"D","amount":"$127.5 million","upfrontCash":"$15.0 million","newsHeadline":"Livzon Acquires Rights to GERD Therapy from Onconic for $127.5 Million","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals for Zastaprazan

    Menu

    Zastaprazan

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Onconic Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Livzon Acquires Rights to GERD Therapy from Onconic for $127.5 Million

              Details:

              Zastaprazan is a P-CAB (potassium-competitive acid-blocking) candidate, a class of drugs that is replacing existing PPIs (proton pump inhibitors) for peptic ulcer disease, including GERD. Livzon will have rights to JP 1366 (zastaprazan) in China, Taiwan, Hong Kong and Macau.

              Lead Product(s): Zastaprazan

              Therapeutic Area: Gastroenterology Product Name: JP 1366

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Livzon Pharmaceutical Group

              Deal Size: $127.5 million Upfront Cash: $15.0 million

              Deal Type: Acquisition March 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY